Register for the program here.

2021 marks 50 years since the National Cancer Act was signed into law. Since then, enormous progress has been made in oncology – from dramatically reduced mortality rates from cancer to the invention of targeted, personalized therapies, and wider access to experimental treatment through clinical trials.

We’ll assess how far we’ve come in 50 years and how much further we can go in the next 50. Join U.S. health officials and advocates on Thursday, June 17 for a conversation half a century in the making.

Ned E. Sharpless, MD

Provided by the National Cancer Institute.

Norman E. “Ned” Sharpless, M.D., was officially sworn in as the 15th director of the National Cancer Institute (NCI) on October 17, 2017. Prior to his appointment, Dr. Sharpless served as the director of the Lineberger Comprehensive Cancer Center at the University of North Carolina (UNC), a position he held since 2014.

Dr. Sharpless was a Morehead Scholar at UNC–Chapel Hill and received his undergraduate degree in mathematics. He went on to pursue his medical degree from the UNC School of Medicine, graduating with honors and distinction in 1993. He then completed his internal medicine residency at the Massachusetts General Hospital and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston.

After 2 years on the faculty at Harvard Medical School, he joined the faculty of the UNC School of Medicine in the Departments of Medicine and Genetics in 2002. He became the Wellcome Professor of Cancer Research at UNC in 2012.

Dr. Sharpless is a member of the Association of American Physicians and the American Society for Clinical Investigation, and is a Fellow of the Academy of the American Association of Cancer Research. He has authored more than 160 original scientific papers, reviews, and book chapters, and is an inventor on 10 patents. He cofounded two clinical-stage biotechnology companies: G1 Therapeutics and Sapere Bio (formerly HealthSpan Diagnostics).

Dr. Sharpless served as Acting Commissioner for Food and Drugs at the U.S. Food and Drug Administration for 7 months in 2019, before returning to the NCI directorship.

Andrew Kaczynski

Provided by CNN.

Andrew Kaczynski is the senior editor and founding member of CNN’s KFILE — the leading investigation team for the social, mobile generation. KFILE is widely praised as a “scoop team,” known for breaking news by scouring the internet through research, fact checking, and investigative reporting. Kaczynski and KFILE have exposed some of the most controversial statements, deceptions and hypocrisies from politicians -- both in office and on the campaign trail including uncovering interviews of Donald Trump’s controversial comments on Howard Stern’s Show.

Kaczynski comes to CNN from BuzzFeed, where he started as a political reporter in 2011. He quickly built a reputation at a young age for unearthing newsworthy archival videos, many of which later went viral. Notable scoops include the revelation that Donald Trump expressed support for the Iraq War in 2002 and evidence Kentucky Senator Rand Paul plagiarized speeches.

Kaczynski has been named to Forbes Magazine’s “30 Under 30: Media” list for 2017. His use of social media has earned him many awards, including The Daily Beast’s 2013 “Beast Best” award for his Twitter Feed and New York Magazine’s 13th most influential Tweeter in New York Ci

Yasmeen Abutaleb

Provided by The Washington Post.

Yasmeen Abutaleb joined The Washington Post in 2019 as a national reporter covering health policy, with a focus on the Department of Health and Human Services, health policy on Capitol Hill and health care in politics. She previously covered health care for Reuters, with a focus on the Affordable Care Act, federal health programs and drug pricing. In 2016, Yasmeen was a lead reporter on a five-part series that examined the rising threat of antibiotic-resistant infections and the inability of the government and health-care industry to address the problem. Yasmeen has also reported in depth on the opioid crisis, changes to Medicaid and political influence on health policies.

Content from AstraZeneca

This content was produced and paid for by a Washington Post Live event sponsor. The Washington Post newsroom was not involved in the production of this content.

One Oncology Community: The Future of Cancer Care Amid the Pandemic and Beyond

This year marks 50 years since the National Cancer Act was signed into law by President Nixon. Since then, extraordinary strides have been made in oncology science and care, evidenced by steady declines in cancer mortality to the advent of screening programs and targeted therapies that have redefined care for millions. As we look at the advancements made over the past 50 years, this segment will focus in on precision medicine, examining its role amid the COVID-19 pandemic and beyond with an emphasis on improving patient outcomes.

Leigh M. Boehmer, PharmD, BCOP

Dr. Leigh Boehmer (pronounced “Beemer”) is the Chief Medical Officer for the Association of Community Cancer Centers (ACCC). In this role, he is responsible for assessing educational needs and designing interventions for multidisciplinary cancer care teams serving patients in community oncology programs and practices. He also serves as a liaison with external stakeholders, including patient advocacy organizations, policy experts, and governmental agencies, to advance the objectives of ACCC membership and projects.

An alumnus of the University of Iowa College of Pharmacy, Dr. Boehmer completed PGY1 and PGY2 oncology residencies at The Johns Hopkins Hospital. He has served as an assistant professor in the Department of Clinical Pharmacy at the St. Louis College of Pharmacy in St. Louis, Missouri, and as an inpatient medical oncology clinical pharmacy specialist at Barnes-Jewish Hospital. Prior to his position with ACCC, he served as Oncology Clinical Pharmacy Specialist at Mercy Cancer Center in Mason City, Iowa. In that capacity he served on multiple hospital and system-level committees tasked with oncology clinical and research standardization and cost savings.

Dave Fredrickson

Dave was appointed Executive Vice President, Oncology Business Unit in October 2017 and is responsible for driving growth and maximising the commercial performance of the AstraZeneca global Oncology portfolio. He has global accountability for marketing, sales, medical affairs and market access in Oncology and plays a critical leadership role in setting the Oncology portfolio and product strategy. Previously, Dave served as President of AstraZeneca K.K. in Japan, and Vice-President, Specialty Care in the US. While in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association. Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions, including Oncology Business Unit Manager in Spain, and strategy, marketing and sales roles in the US. Prior to this, Dave worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy. Dave is a graduate of Georgetown University in Washington DC.